Used in targeted cancer therapy, particularly for treating ovarian cancer and other solid tumors that overexpress the folate receptor alpha (FOLR1). This antibody selectively binds to FOLR1 on cancer cells, enabling precise delivery of cytotoxic agents when conjugated as part of an antibody-drug conjugate (ADC). It helps minimize damage to healthy cells, improving therapeutic efficacy and reducing side effects. Currently utilized as the targeting component in ADCs undergoing clinical trials, showing promise in patients with platinum-resistant disease. Also serves as a reference standard in immunoassay development and biosimilar characterization.